Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 4/2011

01-12-2011 | Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

Promising Prevention Approaches: Tenofovir Gel and Prophylactic Use of Antiretroviral Medications

Authors: Douglas Krakower, Kenneth H. Mayer

Published in: Current HIV/AIDS Reports | Issue 4/2011

Login to get access

Abstract

Thirty years into the global HIV epidemic, the need for effective prevention strategies remains critical. In July 2010, the CAPRISA-004 study demonstrated that topical administration of a gel containing the antiretroviral agent tenofovir decreased the risk of HIV acquisition among at-risk heterosexual women. Subsequently, the iPrEx study reported that prophylactic use of a daily oral tablet containing tenofovir and emtricitabine reduced the risk of HIV acquisition among high-risk men who have sex with men. These studies illustrate the promise of antiretroviral pre-exposure chemoprophylaxis (PrEP) as an innovative prevention approach. This review discusses the rationale for chemoprophylaxis, compares the advantages of topical and oral delivery, outlines recommended safety monitoring, offers principles to guide selection of antiretroviral agents, and highlights potential unintended consequences of PrEP use. If future studies confirm the safety and efficacy of tenofovir gel and oral PrEP, successful implementation of these strategies could significantly impact the HIV epidemic.
Literature
1.
2.
Dieffenbach CW, Fauci AS. Thirty years of HIV and AIDS: future challenges and opportunities. Ann Intern Med. 2011;154(11):766–71.PubMed
3.
•• Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74. This reference reports the results of CAPRISA-004, a community-based, randomized controlled trial that demonstrated the efficacy of topical tenofovir gel in reducing the risk of HIV acquisition by 39% among at-risk heterosexual women in South Africa. PubMedCrossRef
4.
•• Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99. This reference reports the results of iPrEx, a multinational, randomized controlled trial in which daily administration of oral FTC-TDF decreased the risk of HIV acquisition among high-risk MSM and transgender women by 44%. PubMedCrossRef
5.
Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med. 1997;337(21):1485–90.PubMedCrossRef
6.
Schechter M, do Lago RF, Mendelsohn AB, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr. 2004;35(5):519–25.PubMedCrossRef
7.
Garcia-Lerma JG, Cong ME, Mitchell J, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med. 2010;2(14):14ra14.CrossRef
8.
Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials. 2007;2(5):e27.PubMedCrossRef
9.
Mayer KH, Maslankowski LA, Gai F, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006;20(4):543–51.PubMedCrossRef
10.
Hendrix C, Minnis A, Guddera V, et al. MTN-001: a phase 2 cross-over study of daily oral and vaginal TFV in healthy, sexually active women results in significantly different product acceptability and vaginal tissue drug concentrations. [abstract 35LB]. Presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston; February 27-March 2, 2011.
11.
Hillier S. Safety and acceptability of coitally dependant use of 1% tenofovir over six months of use. [abstract BO12-655]. Presented at the Microbicides 2008 Conference. New Delhi, India; February 24–27, 2008.
12.
13.
14.
Anton P, Cranston R, Carballo-Dieguez A, et al. RMP-02/MTN-006: a phase 1 placebo-controlled trial of rectally applied 1% vaginal TFV gel with comparison to oral TDF. [abstract 34LB]. Presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston; February 27–March 2, 2011.
15.
Baeten J, Celum C. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the partners PrEP study [abstract MOAX0106]. Presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Rome, Italy; July 17–20, 2011.
16.
Thigpen MC, Kebaabetswe PM, Smith DK, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 Study. [abstract WELBC01]. Presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Rome, Italy; July 17–20, 2011.
17.
18.
Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006;42(2):283–90.PubMedCrossRef
19.
Szczech LA. Renal dysfunction and tenofovir toxicity in HIV-infected patients. Top HIV Med. 2008;16(4):122–6.PubMed
20.
Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23(6):689–96.PubMedCrossRef
21.
Cooper Ryan D, Wiebe N, Smith N, et al. Systematic review and meta–analysis: renal safety of tenofovir disoproxil fumarate in HIV–infected patients. Clin Infect Dis. 2010;51(5):496–505.PubMedCrossRef
22.
Jacobson DL, Spiegelman D, Knox TK, Wilson IB. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr. 2008;49(3):298–308.PubMedCrossRef
23.
Liu A, Vittinghoff E, Irby R, et al. BMD loss in HIV—men participating in a TDF PrEP clinical trial in San Francisco. [abstract 93]. Presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston; February 27-March 2, 2011.
24.
• Interim Guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011;60(3):65–8. This reference is a summary of interim guidance from the CDC on the use of daily oral chemoprophylaxis with FTC-TDF in high-risk MSM. The authors outline current recommendations around laboratory and clinical monitoring associated with PrEP use in this population.
25.
Liegler T, Abdel-Mohsen M, Atchison R, et al. Drug resistance and minor drug resistant variants in iPrEx. [abstract 97LB]. Presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston; February 27–March 2, 2011.
26.
Kwara A, DeLong A, Rezk N, et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV–infected women receiving long–term highly active antiretroviral therapy. Clin Infect Dis. 2008;46(5):719–25.PubMedCrossRef
27.
28.
Dumond JB, Yeh RF, Patterson KB, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS. 2007;21(14):1899–907.PubMedCrossRef
29.
Van Rompay KK, Matthews TB, Higgins J, et al. Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol. 2002;76(12):6083–92.PubMedCrossRef
30.
Dumond JB, Patterson KB, Pecha AL, et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr. 2009;51(5):546–53.PubMedCrossRef
31.
Nel A, Smythe S, Young K, Malcolm K, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr. 2009;51(4):416–23.PubMedCrossRef
32.
Patton DL, Sweeney YT, Balkus JE, et al. Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations. Antimicrob Agents Chemother. 2007;51(5):1608–15.PubMedCrossRef
33.
Ghosn J, Chaix ML, Peytavin G, et al. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS. 2004;18(14):1958–61.PubMedCrossRef
34.
Patel SM, Johnson S, Belknap SM, et al. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr. 2004;35(2):120–5.PubMedCrossRef
35.
Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727–32.PubMedCrossRef
36.
Amico KR, Liu A, McMahan V, et al. Adherence indicators and PrEP drug levels in the iPrEx study. [abstract 95LB]. Presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston; February 27–March 2, 2011.
37.
Stirratt MJ, Gordon CM. Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research. Curr HIV/AIDS Rep. 2008;5(4):186–92.PubMedCrossRef
38.
Guest G, Shattuck D, Johnson L, et al. Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis. 2008;35(12):1002–8.PubMed
39.
Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54(5):548–55.PubMedCrossRef
40.
Mayer KH, Krakower D, Novak DS, et al. On-line assessment of Pre-Exposure Prophylaxis (PrEP) knowledge, attitudes and experience among at risk American Men who have Sex with Men (MSM) before and after the publication of the iPrEx trial results. [abstract TUPE360]. Accepted to the 6th IAS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Rome, Italy; July 17–20, 2011.
41.
Mugavero MJ, Norton WE, Saag MS. Health care system and policy factors influencing engagement in HIV medical care: piecing together the fragments of a fractured health care delivery system. Clin Infect Dis. 2010;52(Supplement 2):S238–46.CrossRef
42.
Yarnall KS, Pollak KI, Ostbye T, Krause KM, Michener JL. Primary care: is there enough time for prevention? Am J Public Health. 2003;93(4):635–41.PubMedCrossRef
43.
Desai K, Sansom SL, Ackers ML, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS. 2008;22(14):1829–39.PubMedCrossRef
44.
Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48(6):806–15.PubMedCrossRef
45.
Walensky R, Park J-E, Wood R, Freedberg K, Scott C, Bekker LG, et al. Cost effectiveness of PrEP for HIV infection in South Africa. [abstract 37LB]. Presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston; February 27–March 2, 2011.
46.
47.
Montano DE, Phillips WR, Kasprzyk D, Greek A. STD/HIV prevention practices among primary care clinicians: risk assessment, prevention counseling, and testing. Sex Transm Dis. 2008;35(2):154–66.PubMedCrossRef
48.
Epstein RM, Morse DS, Frankel RM, et al. Awkward moments in patient-physician communication about HIV risk. Ann Intern Med. 1998;128(6):435–42.PubMed
49.
Peterman TA, Lin LS, Newman DR, et al. Does measured behavior reflect STD risk? An analysis of data from a randomized controlled behavioral intervention study. Project RESPECT Study Group. Sex Transm Dis. 2000;27(8):446–51.PubMedCrossRef
50.
Buchbinder SP, Liu A. Pre-exposure prophylaxis and the promise of combination prevention approaches. AIDS Behav. 2011;15 Suppl 1:S72–9.PubMedCrossRef
51.
Siegfried N, Muller M, Deeks JJ, Volmink J. Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev. 2009(2):CD003362.
52.
Chigwedere P, Seage GR, Lee T-H, Essex M. Efficacy of antiretroviral drugs in reducing mother-to-child transmission of HIV in Africa: a meta-analysis of published clinical trials. AIDS Res Hum Retrovir. 2008;24(6):827–37.PubMedCrossRef
53.
Cohen Myron S, Gay Cynthia L. Treatment to prevent transmission of HIV–1. Clin Inf Dis. 2010;50(3):S85–95.CrossRef
54.
Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092–8.PubMedCrossRef
55.
Metadata
Title
Promising Prevention Approaches: Tenofovir Gel and Prophylactic Use of Antiretroviral Medications
Authors
Douglas Krakower
Kenneth H. Mayer
Publication date
01-12-2011
Publisher
Current Science Inc.
Published in
Current HIV/AIDS Reports / Issue 4/2011
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-011-0094-4

Other articles of this Issue 4/2011

Current HIV/AIDS Reports 4/2011 Go to the issue

Erratum

Erratum to: Management of Fat Accumulation in Patients with HIV Infection

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

Mental Health: A Focus on Stress, Coping, and Mental Illness as it Relates to Treatment Retention, Adherence, and Other Health Outcomes

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

A Global Perspective on Complementary and Alternative Medicine Use Among People Living with HIV/AIDS in the Era of Antiretroviral Treatment

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

Neurocognitive Impact of Antiretroviral Treatment: Thinking Long-Term

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

Substance Use: Impact on Adherence and HIV Medical Treatment

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

Link to Slower Access to Care: What is the Stigma? An Indian Perspective
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits